Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 177

Results For "drug"

3024 News Found

Ashland announces Klucel xtend HPC matrix former for extended-release tablets
News | October 11, 2022

Ashland announces Klucel xtend HPC matrix former for extended-release tablets

The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.


Lupin partners global Agencies to support tuberculosis prevention treatment
News | October 09, 2022

Lupin partners global Agencies to support tuberculosis prevention treatment

Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price


Pfizer acquires Global Blood Therapeutics
News | October 09, 2022

Pfizer acquires Global Blood Therapeutics

Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community


Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
News | October 07, 2022

Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults

Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).


Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals
News | October 07, 2022

Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals

DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.


Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
Drug Approval | October 07, 2022

Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets

Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.


Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
People | October 07, 2022

Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.


Lupin receives approval from USFDA for Darunavir Tablets
Drug Approval | October 05, 2022

Lupin receives approval from USFDA for Darunavir Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.


Casper Pharma receives EIR from USFDA for its PAI
Drug Approval | October 05, 2022

Casper Pharma receives EIR from USFDA for its PAI

The inspection concluded with no observation (FDA-483) issued.


Zydus receives USFDA tentative approval for Amantadine Extended-Release capsules
Drug Approval | October 05, 2022

Zydus receives USFDA tentative approval for Amantadine Extended-Release capsules

Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data